Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss how genetic neurology is shaping the next wave of biotech and therapeutic discoveries and the latest innovations in Phase 1 Clinical Trials. They will also explain why Australia is the preferred destination for clinical research and how to fast track Phase 1 studies at a fraction of cost compared to US and Europe.

In this webinar, attendees will learn about the growing field of genetic neurology, with a focus on therapeutic discoveries, innovations in Phase I trials and leveraging the expertise of Australian-based experts and clinical trial providers.

Inspired by breakthroughs in the genetics of epilepsy, Massachusetts-based Praxis Precision Medicines is focused on both rare genetic epilepsies and more common central nervous system (CNS) disorders. To bring their innovations through the first phase of discovery and validation, Praxis sought the expertise of Australia’s largest Phase 1 clinical provider, Nucleus Network.

The discovery of gene variants that cause epilepsy has been led by a group of world-class academic researchers in Melbourne, Australia. It was this hotbed of epilepsy and genetics leaders that first attracted Praxis to Melbourne. However, when the company began to explore where to conduct their initial Phase 1 studies, they were grateful to find Nucleus Network in the same city, with just the right expertise and capabilities. Moreover, with a population of over 5 million, Melbourne has been an ideal location for Praxis’ studies. According to Praxis Senior Medical Director, Dr. Gabi Belfort, Nucleus Network offered an excellent solution for even highly technical studies involving the monitoring of brain waves by electroencephalography (EEG).

One critical study that was conducted at Nucleus involved measuring the pharmacodynamic effect (on EEG) of one of Praxis’ lead molecules in a multiple ascending dose study. The data collected in this study facilitated dose selection for a subsequent trial in patients with a psychiatric disease. Following on from the success of these initial trials, Praxis will be undertaking a titration study with Nucleus Network for another therapeutic, which may be useful for treating epilepsy or movement disorders.

Join Cameron Johnson, CEO, Nucleus Network and Gabi Belfort, MD, PhD, Senior Medical Director, Praxis Precision Medicines in a live webinar on Tuesday, May 19, 2020 at 4pm EST.

For more information or to register for this event, visit Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts.


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
+1 (416) 977-6555 x 352
Email >
Visit website